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Insulin-Resistant Diabetes Mellitus and Insulin Receptor Antibodies
Variable association with acanthosis nigricans
Jose Goldman, MD, PhD*

Two patients with severe insulin-resistant
diabetes
mellitus
and anti-insulin
receptor autoantibodies
are reported
here.
A marked decrease in the number of accessible
insulin
receptors was found in the monocytes
of one
patient.
Otherwise,
the Insulin receptors were of normal
affinity
compared to those of normal controls. Acanthosis
nigricans
was not present in one patient, and in the other patient it

preceded the diagnosis of diabetes by ten years. We conclude that although acanthosis nigricans and insulin resistance are frequently associated, they probably do not bear a
pathogenetic
relationship
to each other. Therefore,
the
investigation
of anti-insulin
receptor antibodies Is advisable
in unexplained
insulin-resistant
diabetes even if acanthosis
nigricans is absent.

I n s u l i n resistance may d e v e l o p as a result of a n u m b e r of
mechanisms, namely, excessive plasma levels o f insulin
antagonists (1), secretion of a b n o r m a l insulin (2,3), and
target cell defects (4,5). Recent advances in o u r k n o w l e d g e
of the physiology of insulin action have shed light o n this
last category of causes for insulin insensitivity. Insulin
receptor deficiencies of either primary or secondary o r i g i n
have b e e n d e m o n s t r a t e d in m a t u r i t y - o n s e t d i a b e t e s
mellitus (6,7), obesity (8-10), and the t y p e A syndrome of
acanthosis nigricans and insulin resistance (11). Also, defects o c c u r r i n g distally to the insulin receptor interaction
(12-13) and c i r c u l a t i n g a u t o i m m u n e antibodies directed
against the insulin receptor (4,11,14-16) have been s h o w n
to o c c u r in insulin-resistant diabetics. These anti-insulin
receptor antibodies account for the insulin unresponsiveness in the t y p e B syndrome of acanthosis nigricans and
insulin resistance (11). W e are r e p o r t i n g here t w o cases of
diabetes associated w i t h severe insulin resistance and antiinsulin receptor antibodies, one of w h i c h had the unusual
feature o f l a c k i n g acanthosis nigricans. Such a feature
indicates that this skin disorder does not necessarily acc o m p a n y the t y p e B s y n d r o m e of insulin resistance.

Case Reports
Case 1
This 69-year-old obese white woman had diabetes mellitus diagnosed 13 months previously, without diabetic ketoacidosis or any
long-range complications. Because her diabetes was uncontrolled
with treatment consisting of a 1400 calorie diet, insulin therapy
was initiated. However, an increasing insulin dosage of up to 200
units of pork Lente insulin per day failed to improve her metabolic
control. The patient's past medical history included bronchial
asthma, essential hypertension, ischemic heart disease with angina pectoris, status postmyocardial infarction and congestive
heart failure, peripheral deep vein thrombosis, pulmonary embolism, hiatal hernia, and reflux esophagitis. Additional therapy
consisted of aldactazide two tablets, aldomet 750 mg, digoxin
0.25 mg, and terbutaline 10 mg daily. Both her mother, who had
died at age 70, and a sister had uncomplicated adult onset
diabetes mellitus. Physical examination failed to reveal any evidence of acanthosis nigricans.
Optimal diabetic control could not be attained despite dietary
compliance and insulin replacement as described above. The
patient died suddenly of a cardiorespiratory arrest associated with
an acute m y o c a r d i a l i n f a r c t i o n 18 days after her hospital
admission.
Case 2
A 31-year-old white woman had an eleven-year history of diabetes complicated by peripheral neuropathy, proliferative retinopathy, and vitreous hemorrhage; these latter problems had
been treated with laser therapy and vitrectomy. No ketoacidosis or
other late diabetic complications were present. Additional medical problems included essential hypertension, severe depression,
obesity, and recurrent galactorrhea associated with phenothiazine
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treatment. Galactorrhea resolved after this medication was discontinued. The patient's one pregnancy had ended prematurely in
miscarriage. She never used oral contraceptives. Her therapy
consisted of a 1200 calorie diet, single peak NPH pork insulin 200
units, dyazide two tablets, minipress 20 mg, and haldol 10 mg
daily. Acanthosis nigricans had been noted first at age 10 and was
confirmed duringthe physical examination. A sister ofthe patient
apparently had acanthosis nigricans, but she was not known to
have diabetes and was not available for clinical studies.

ated hemoglobin measurements amounted to 13.2%.
Plasma Cortisol and growth hormone levels were within the
normal range, and insulin antibodies were undetectable. Fasting plasma insulin and C-peptide concentrations
were 36.5 /xU/ml and 5.4 ng/ml, respectively, and the
insulin and C-peptide responses to intravenous glucagon
stimulation indicated that a normal pancreatic beta cell
reserve was present (Table I).
TABLE I

Methods

Glucagon Stimulation Test

Insulin antibodies were measured by a previously reported
procedure (17). Insulin was labeled with ^^=1 (Amersham
Corporation, Arlington, IL) according to a modification of
the method of Freychet, et al (18). Plasma free insulin and
C-peptide immunoreactivities were assessed by the procedures of Nakagawa, et al (19) and Kuzuya, et al (20),
respectively. Plasma globulins were isolated by precipitation w i t h 50% a m m o n i u m sulfate. C i r c u l a t i n g m o n o nuclear blood cells were isolated with Ficoll-Hypaque
gradients (21), and monocytes were counted after
cytochemical staining with a nonspecifc esterase method
(22). Insulin reserve was measured by means of a glucagon
stimulation test (23).

Time
(min)

Plasma
Insulin
(AtU/ml)

Plasma
C-Peptide
(ng/ml)

1

0
5
10
20

36.5
62.5
52.4
36.4

5.4
6.5
6.4
6.0

2'

0
5
10
20

28.2
61.0
37.6
50.8

2.1
3.3
3.2
3.0

Patient

* Free plasma insulin and C-peptide levels were measured because insulin
antibodies were present.

Responsiveness to insulin was assessed by a modification
of the procedure of Shen, et al (24), which consists of a
constant rate intravenous infusion of insulin (80 mU/min)
and glucose (6 mg/Kg/min). Epinephrine and propanolol
used in the original procedure were omitted in the infusate
because of their effect on the hepatic production of glucose
(25-30). Felig and Wahren (31) have shown that at levels of
plasma insulin comparable to those attained in this study,
splanchnic production of glucose is suppressed. Therefore,
the corresponding steady state plasma glucose levels reflect the subject's responsiveness to insulin. The omission
of epinephrine and propanolol in the infusate resulted in
persistent endogenous insulin secretion which was assessed by measurement of plasma C-peptide levels.

The second patient showed an average fasting plasma
glucose of 165 mg/dl (range: 93-265 mg/dl), and a mean
random plasma glucose value of 205 mg/dl (range: 97-377
mg/dl). Glycosylated hemoglobin was 13.5%. Fasting
plasma-free insulin and C-peptide values were 28.2 /nU/ml
and 2.1 ng/ml, respectively (Table I). Plasma insulin antibody titers were 0.9 and 1.5 units/liter on two different
occasions. Intravenous glucagon stimulation resulted in a
normal pancreatic beta cell response, as indicated by the
plasma-free insulin and C-peptide concentrations (Table I).
Negative results were obtained for an assortment of autoimmune antibodies that included antinuclear factor, antimicrosomal (thyroid), antiparietal (gastric) and antismooth
muscle antibodies, rheumatoid factor, and direct and indirect Coombs tests. An overnight plasma Cortisol level after
a dose of dexamethasone 1 mg p.o. was 1.9 ju,g/dl, and
urinary-free Cortisol was 44.4 p,g/24 hr. Plasma growth
hormone and prolactin levels were within normal ranges.
Plasma i m m u n o g l o b i n concentrations were IgG 971
mg/dl, IgM 142 mg/dl, IgA 165 mg/dl, and IgE <0.04
mg/dl, all within normal limits.

Control subjects were 34 lean, normal individuals, 15 men
and 19 women; all were within ± 15% of ideal body
weight according to standard Metropolitan Life Insurance
Co tables. All other assays were done by standard radioimmunoassays and clinical methods. Single component pork
insulin was a gift of Dr. Ronald E. Chance of Eli Lilly and
Co, Indianapolis, Ind. Dr. Ake Lernmark of the Hagedorn
Research Laboratory, Gentoften, Denmark, supplied the
antibody for the insulin radioimmunoassay.

Steady state plasma glucose concentrations during a standardized insulin-glucose infusion (see Methods) amounted
to 234 and 273 mg/dl for patients 1 and 2, respectively
(Table II). Both values are significantly higher that the
normal control of 72 ± 3.9 mg/dl (average ± SEM) for the
same parameter and indicate the presence of severe insulin

Results
The first patient had average daily random plasma glucose
levels of 185 mg/dl (range: 99-249 mg/dl), and glycosyl-
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resistance. Steady state plasma insulin levels were similar
for both patients and the control group (Table II), further
supporting the implication of abnormal responsiveness to
insulin in these patients. Endogenous secretion of insulin
was not suppressed during the insulin-glucose infusion as
indicated by the comparable steady state plasma C-peptide
values in both patients and control subjects (Table II).

sulinemia is the result of target organ resistance to insulin.
Our two patients fulfill these conditions. Furthermore,
suboptimal metabolic control as evidenced by hyperglycemia and high levels of glycosylated hemoglobin was
present simultaneously with daily insulin dosages of 200
units and appropriate dietary therapy. Since insulin requirements of 200 units per day or higher have been used to
define severe refractoriness to this hormone (1), both patients had marked insulin resistance.

T A B L E II

Obesity is the most common cause of insulin resistance,
and both patients were overweight. However, unresponsiveness to insulin in obesity is usually mild to moderate
and reverses after short-term or chronic caloric restriction
(8). In both patients resistance to insulin and hyperglycemia were severe and persisted despite consistent diets
of 1200 and 1400 calories a day, respectively. Also, the
insulin receptor deficiency that accounts for the hormone
resistance in obesity (11) is usually milder than the markedly decreased number of receptors demonstrated in the
second patient. Therefore, obesity per se cannot explain
the severe insulin resistance of either patient. Hormonal
antagonists to insulin action were secreted in normal levels
and were also normally suppressible. Circulating insulin
antibodies were either undetectable (patient 1) or were
present in titers too low to be consistent with the severity of
the insulin resistance. Insulin serum binding capacities of
55 units/liter or higher have been correlated with daily
requirements of 200 or more units of insulin and are
associated with severe insulin resistance (1).

Responsiveness to Insulin

Patient

SSPG
(mg/dl)

SSPI
(^U/ml)

SSPC
(ng/ml)

1
2-

234
273

82
91

8.1
3.2

Controls
(n=34)

72
±3.9

91
±4.9

2.0
±0.2

* Free plasma insulin and C-peptide levels were measured because insulin
antibodies were present. SSPG, SSPI and SSPC stand for steady state
plasma glucose, insulin and C-peptide, respectively.

Anti-insulin receptor antibodies were present in both patients (Fig. 1). The serum of patient 1 inhibited specific
binding o f ' " l - i n s u l i n to normal isolated monocytes to an
extent of 98.6 and 98.4% at serum dilutions of 1/7 and
1/70, respectively. Globulins isolated from the serum of
patient 1 also produced 66.5 and 33.1% inhibition of'^=1insulin binding to specific receptors at concentrations correspondingto serum dilutions of 1/7 and 1/70, respectively
(Fig. 1, upper panel). The lesser inhibition of insulin binding to receptors seen with the isolated globulins of patient 1
is probably due to incomplete recovery of serum globulins.
Similar findings were observed in patient 2, in whom the
degree of inhibition was 87.0 and 70.2% for the serum and
92.2 and 67.3% for the isolated globulins at equivalent
serum dilutions of 1/7 and 1/70, respectively (Fig. 1, lower
panel).

Studies on the circulating monocytes ofthe second patient
revealed a severe deficiency in the number of insulin
receptors, and in both patients serum insulin receptor
antibodies could be demonstrated. In consequence, these
patients appear to have the type B syndrome of insulin
resistance (11). The pathogenesis o f t h e insulin unresponsiveness in this syndrome involves mainly the blocking of
insulin receptors by the antireceptor autoantibodies (32,
33), although a decrease in the binding affinity of the
accessible receptor sites has also been reported on the
patients' monocytes (34). However, removing the specific
antibodies from the surface receptor sites of monocytes
from type B patients has both increased the insulin binding
and normalized the receptor binding affinity (35). Also,
when fibroblasts and circulating mononuclear cells were
isolated from type B patients and followed by long-term
culture, cells with normal insulin binding characteristics
were produced, indicating that the receptor abnormalities
of these cells are not intrinsic but probably secondary to
perturbation by the antireceptor antibodies (35). Further
evidence is provided by reports that resistance to insulin
was reversed and insulin receptor b i n d i n g parameters were normalized after immunosuppressive therapy

Characterization of the insulin receptors of circulating
monocytes could only be performed on our second patient.
Fig. 2 shows the markedly decreased insulin binding to
peripheral monocytes isolated from patient 2 (open circles)
compared to the average binding to insulin receptors from
34 normal, lean controls (closed circles). Scatchard plots
obtained from the same set of binding data reveal that the
binding curves of patient 2 and the normal controls are
parallel, which indicates similar receptor binding affinities
but with decreased numberof accessible insulin receptors
(Fig. 3).

Discussion
The development of diabetes mellitus concomitantly with
seemingly normal pancreatic beta cell reserve and hyperin-
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Fig. 1
Inhibition of insulin binding to specific receptors of normal human monocytes by patients' serum and serum globulins. "M-insulin (5x10-"M) was
Iro" r-'*.
^ *".*P^7*'0" 40-60x10' mononuclear cells isolated from the blood of normal subjects. Incubations were carried out to equilibrium at

carried out by acidification and adsorption of free insulin onto dextran-coated charcoal followed by pH neutralization. Open symbolsrepresentdata
obtained with patients' serum and closed symbols data from experiments with isolated globulins.

(36) and multiple plasmapheresis (37) that brought about a
decrease in antireceptor antibody titers. Paradoxically,
these antireceptor antibodies stimulate glucose transport
and metabolism in adipocytes and muscle cells (38,39) and
activate pyruvate dehydrogenase and acetylcoenzyme A
carboxylase from fat cells (40). These findings seem to
indicate that the antireceptor antibodies are heterogeneous
and comprise both blocking and activating species that
differ in their specificity for various antigenic determinants
on or near the insulin receptor. It is also noteworthy that
spontaneous remission of insulin resistance and development of hypoglycemia have occurred in several type B
patients (41,42), which could be explained by a change in
the relative concentrations of blocking and activating antireceptor antibodies.

antibodies
located on
tients with
against the
plate (44).

directed against the receptor for thyrotropin
the thyroid plasma membranes (43), and pamyasthenia gravis have circulating antibodies
acetylcholine receptor of the myoneural end-

The pathogenetic relationship between acanthosis
nigricans and insulin resistance is still obscure. Estrogen
therapy in two type A patients has resulted in partial and
complete remissions oftheir acanthosis nigricans, respectively, without change in either insulin resistance or the
receptor abnormalities (34). A similar observation has been
reported in a patient with acanthosis nigricans and insulin
resistance due to a postreceptor defect (13). Insulin receptor autoantibodies and severe insulin resistance have also
been described in the absence of acanthosis nigricans (45),
although the patient later developed this skin disorder (AH
Rubenstein, personal communication). Acanthosis
nigricans was noted in our second patient long before

Other clinical entities caused by antireceptor autoantibodies have also been described. Graves' disease is characterized by the presence of both blocking and stimulating
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Fig.2
Displacement of "M-insulin by varying concentrations of cold insulin from monocytes of patient 2 (open circles) and normal controls (closed circles).
Experimental conditions were similar to those in Fig. 1. The binding data have been normalized to a monocyte count of 10' cells/ml. Normal control
values represent the mean of 34 measurements on different individuals placed on a 200 gm carbohydrate diet for three days before the study. Vertical
bars represent the standard error of the mean.

diabetes was diagnosed, and no evidence for it existed in
patient 1. These observations suggest that the pathogenesis
of acanthosis nigricans and insulin resistance are independent ofeach other. As a corollary, it is advisable to investigate the presence of insulin receptor antibodies in patients
with otherwise unexplained insulin resistance even if
acanthosis nigricans is absent.
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